

Review



**Cite this article:** Wang J, Beecher K. 2021

TSPO: an emerging role in appetite for a therapeutically promising biomarker.

*Open Biol.* **11**: 210173.

<https://doi.org/10.1098/rsob.21.0173>

Received: 10 June 2021

Accepted: 13 July 2021

**Subject Area:**

biochemistry/neuroscience/cognition

**Keywords:**

TSPO, obesity, appetite, RIM-BP1, neurosteroids, tanycytes

**Author for correspondence:**

Joshua Wang

e-mail: [jj.reilly@hdr.qut.edu.au](mailto:jj.reilly@hdr.qut.edu.au)

# TSPO: an emerging role in appetite for a therapeutically promising biomarker

Joshua Wang and Kate Beecher

Addiction Neuroscience and Obesity Laboratory, School of Clinical Sciences, Faculty of Health, Translational Research Institute, Queensland University of Technology, Brisbane, Queensland, Australia

JW, 0000-0002-9458-5665; KB, 0000-0001-7462-1158

There is accumulating evidence that an obesogenic Western diet causes neuroinflammatory damage to the brain, which then promotes further appetitive behaviour. Neuroinflammation has been extensively studied by analysing the translocator protein of 18 kDa (TSPO), a protein that is upregulated in the inflamed brain following a damaging stimulus. As a result, there is a rich supply of TSPO-specific agonists, antagonists and positron emission tomography ligands. One TSPO ligand, etifoxine, is also currently used clinically for the treatment of anxiety with a minimal side-effect profile. Despite the neuroinflammatory pathogenesis of diet-induced obesity, and the translational potential of targeting TSPO, there is sparse literature characterizing the effect of TSPO on appetite. Therefore, in this review, the influence of TSPO on appetite is discussed. Three putative mechanisms for TSPO's appetite-modulatory effect are then characterized: the TSPO–allopregnanolone–GABA<sub>A</sub>R signalling axis, glucosensing in tanycytes and association with the synaptic protein RIM-BP1. We highlight that, in addition to its plethora of functions, TSPO is a regulator of appetite. This review ultimately suggests that the appetite-modulating function of TSPO should be further explored due to its potential therapeutic promise.

## 1. Introduction

An inflamed brain is an emerging phenotype of obesity [1,2]. Specifically, neuroinflammation at the hypothalamus has been shown to dampen anorexigenic neuronal activity and promote orexigenic neuronal activity [3,4]. This foundational finding has implicated neuroinflammation as a cause of appetite dysfunction, and subsequently, diet-induced obesity. In mimicking the obesogenic Western diet, rodent studies in which animals were fed a high-fat [3], high-sugar [5–7] or combination high-fat high-sugar [8] diet precipitated hypothalamic neuroinflammation. The cellular mechanisms of diet-induced inflammation are currently being investigated, with microglia [9–13] and astrocytes [14,15] adopting pro-inflammatory states in response to overnutrition.


The translocator protein of 18 kDa (TSPO) is a modulator of neuroinflammation [16–19] that may also regulate diet-induced obesity [20]. TSPO is located predominately within the outer mitochondrial membrane [21] in various tissues where it regulates a plethora of processes, including steroidogenesis [22], mitochondrial energetics [23], porphyrin synthesis [24,25] and apoptosis [26]. TSPO is also expressed in non-diseased human and wild-type rodent brains in astrocytes, microglia and neurons in a region-dependent manner [27–29]. TSPO is expressed sparsely throughout the brain, but is concentrated at the olfactory bulb, the choroid plexus, the cerebellum and the ependyma (reviewed in [27]). However, the regional and cellular expression of TSPO is altered across a variety of disease states [30]. TSPO is most well known as a marker of neuroinflammation as its expression is constitutively low but greatly increased in pro-inflammatory microglia [31–33]. Consequently, an array of TSPO ligands have been developed for positron emission tomography (PET) imaging,

allowing for *in vivo* human data on neuroinflammation to be generated [34]. As a result, TSPO has a variety of highly specific ligands [35–37] available to dissect its function, as well as a clinically used agonist that is anxiolytic: etifoxine [38]. Therefore, TSPO may represent a therapeutically viable target for the treatment of diet-induced obesity. Although it has been implicated in feeding previously [39,40], how TSPO regulates appetite in the brain has not been explicitly explored. This review discusses three putative mechanisms for how brain TSPO may alter appetitive circuits: the TSPO–allopregnanolone–GABA<sub>A</sub>R (TAG) axis, modulation of tanyctic glucosensing and altering RIM-BP1 function. By building on these foundational findings, future research may identify a strategy to target TSPO as an obesity treatment.

## 2. TSPO increases the efficiency of GABAergic transmission in appetitive circuits via the TAG axis

The channel-like appearance of TSPO, as well as the identification of an evolutionarily conserved cholesterol recognition amino acid consensus sequence [41], suggests that it is involved in cholesterol transport. Cholesterol import into the mitochondrial intermembrane space is the rate-limiting process in the synthesis of neurosteroids [42,43]: brain-specific steroids that are synthesized *de novo* within the brain [44,45]. Many studies demonstrate that TSPO ligands, including TSPO's endogenous ligands, the endozepines [46], influence the production of neurosteroids [45,47–50]. However, recent studies have shown that TSPO knockout models maintain neurosteroid synthesis [51–54], dismissing the long-held belief that TSPO knockout was lethal in rodent models [55]. TSPO is therefore not essential for cholesterol import, but heavily influences this process [56,57]. As a result, the original name 'peripheral benzodiazepine receptor' [58] is now largely replaced by TSPO to better reflect its hypothesized function in cholesterol transport [22].

The neurosteroids that TSPO assists in synthesizing are produced in both neurons and glia [59] throughout many brain regions [60]. The specific neurosteroids that TSPO produces are altered by different TSPO ligands and there is conflicting evidence to implicate TSPO in the production of specific neurosteroids [61]. However, allopregnanolone production has universally been found to be increased in the presence of a TSPO ligand, including PK11195 [18,62], etifoxine [63,64], FGIN1-27 [65,66], XBD-173 [63], YL-IPA08 [67] and CB-34 [62]. While traditional steroids act through nuclear receptors to alter transcriptional events, neurosteroids act independently of nuclear steroid hormone receptors [68,69]. Instead, neurosteroids bind to an allosteric site on ionotropic GABA<sub>A</sub> receptors [70–73]. The most potent of these neurosteroids, allopregnanolone, acts as a positive allosteric modulator of GABA<sub>A</sub>Rs [74] and increases its effectiveness at producing inhibitory potentials. GABA<sub>A</sub>Rs are widely expressed throughout the brain and have been implicated in the regulation of appetite [75]. Therefore, it is not surprising that allopregnanolone is a major regulator of feeding [76]. Based on these findings, we hypothesize that TSPO influences sucrose overconsumption through a potential signalling axis composed of allopregnanolone and GABA<sub>A</sub>Rs as downstream effectors. This signalling cascade is termed the TAG axis (figure 1).




**Figure 1.** The TAG axis. Allopregnanolone synthesis begins with cholesterol's import into the mitochondrial matrix through TSPO. This cholesterol import is the rate-limiting step in allopregnanolone synthesis. As a hydrophobic molecule, allopregnanolone is then able to diffuse freely to surrounding cell types, including GABAergic synapses. When bound to GABA<sub>A</sub>Rs, allopregnanolone acts as a positive allosteric modulator, increasing the activity of these receptors. Figure produced using Biorender software.

Given that TSPO modulates the rate-limiting step in the production of allopregnanolone [42,43], alterations in TSPO expression or activity would hypothetically alter the overall activity of the TAG axis.

## 3. Tanyctic TSPO modulates glucosensing

Tanycytes were first described as lengthened bipolar ependymal cells lining the ventral portion of the third ventricle [77]. Their name is derived from the Greek term *tanus*, meaning stretched/elongated [78]. Although there were transient hypotheses that tanycytes were a neuronal subpopulation [79], they are now considered radial glial-like cells that maintain stem cell phenotypes [80]. There are now promising foundational single-cell transcriptomic data available for tanycytes [81,82], which has resolved five transcriptionally unique tanyctic cell types [81]. Recently, transgenic labelling of tanycytes has confirmed a number of their structural properties [83]. Tanycytes consist of a proximal cell body lining the ventricular surface of the third ventricle, with a single distal process that traverses the arcuate nucleus, ventromedial nucleus and dorsomedial nucleus of the hypothalamus, contacting capillaries and the neural parenchyma (figure 2*a*). Tanycytes therefore represent a three-way physical connection with feeding-related hypothalamic circuits, the cerebrospinal fluid (CSF) and the circulation [84]. It is, therefore, not surprising that an emerging body of research now implicates tanycytes in appetite modulation [85]. Additionally, tanycytes have some of the highest expression of TSPO in the entire brain [27,39], likely due to the fact that TSPO is expressed highly in explanted neural stem cells [86].

Given that CSF contents are proportional to blood contents for many solutes such as glucose [87], the structure and location of tanycytes allow them to monitor metabolic cues from the CSF to subsequently signal these alterations to appetite-related neurons in the hypothalamus. Firstly, the ventricular surface of tanycytes are equipped with microvilli extending into the lumen of the third ventricle [88], allowing them to sense a variety of nutrient signals in the CSF such as



**Figure 2.** TSPO regulates glucosensing in tanycytes. (a) Schematic of the coronal section of the rodent brain. Tanycytes continuously line the ventral portion of the third ventricle (right-hand side tanycytes removed for clarity), and their basal projections infiltrate the surrounding dorsomedial hypothalamus (DMH), ventromedial hypothalamus (VMH) and arcuate nucleus (ARC). These projections contact both the hypothalamic parenchyma, as well as capillaries. (b) TSPO and tanycytic glucosensing. Glucose is present in the CSF at concentrations that reflect blood glucose levels. When the CSF passes the ventral portion of the third ventricle, it is transported into tanycytes via glucose transporter 2 (GLUT2). Then, glucose is oxidized in the mitochondria to produce ATP. This process is positively regulated by TSPO. The resultant ATP is then used to activate adjacent tanycytes by passing through connexin 43 hemichannels (Cx43). Tanycytic ATP is then also used to depolarize adjacent AgRP (orexigenic) and POMC (anorexigenic) neurons by binding to purinoceptors (predominately the P2X4 receptor), ultimately changing the appetitive state of the brain. Figure produced using Biorender software.

glucose [89–91], artificial sweeteners [92], amino acids [93] and lipids [94,95], which ultimately influence the transcriptional state of these cells [81,96]. Depending on nutritional status, tanycytes can regulate the blood–brain barrier and the permeability of CSF constituents [97]. For example, tanycytes release vascular endothelial growth factor (VEGF) under fasting conditions, resulting in an increased permeability of metabolic signals to hypothalamic neurons [98]. Overnutrition also alters tanycytic control over metabolic signalling; blocking leptin [99] and ghrelin [100] from reaching the hypothalamic parenchyma, where they would normally modulate hypothalamic neurons to alter the appetitive state [101,102]. Tanycytes also directly modulate these neurons by altering their expression of orexigenic and anorexigenic neuropeptides [39,91,103–106]. The role of tanycytes in appetite has been confirmed through many loss-of-function studies; tanycyte ablation [105,107,108] and genetic ablation of tanycytic glucosensing machinery [103,104,106] alter feeding and body weight.

As previously stated, TSPO is highly expressed in tanycytes [27,39]. Additionally, tanycytes respond to inflammatory signals by producing chemokines that modulate feeding, suggesting a possible role for TSPO in tanycyte-modulated appetite [109]. Recently, it was shown that genetic ablation of tanycytic TSPO decreases food consumption in mice fed a

high-fat diet [39]. Additionally, administering the TSPO antagonist PK11195 into the third ventricle also decreases feeding in an identical animal model [39]. There is further evidence to suggest that TSPO is important for the function of tanycytes in metabolic homeostasis. For example, tanycytes secrete diazepam binding inhibitor (DBI)—the endogenous ligand for TSPO [110–112]. However, DBI is post-translationally cleaved into a number of endozeptin products, some of which do not interact with TSPO [113]. It is therefore unknown at this stage how DBI or its TSPO-binding cleavage product triakontaheptaneuropeptide [114] mediate tanycyte function. However, there is emerging evidence that has led us to hypothesize that tanycytic TSPO regulates appetite by altering ATP production during glucosensing.

TSPO has a potential role in modulating how tanycyte glucosensing affects feeding neurons within the hypothalamus. Upon sensing glucose in the CSF, tanycytes are activated through an ATP wave [90] propagated by connexin-43 gap junctions between adjacent tanycytes [115]. Activated tanycytes also release ATP, which then diffuses into the arcuate nucleus, where it depolarizes both orexigenic and anorexigenic neuronal populations [116,117]. *In vivo*, tanycytic activation caused hyperphagia only in the fed state [116], demonstrating that aberrant tanycyte signalling can override appetite

**Table 1.** Changes in brain TSPO due to overnutrition.

| species                   | age   | conditions   | TSPO expression measurement method  | regions assessed  | TSPO change  | regions with change  | reference |
|---------------------------|---|--|---|---|--|--|-----------|
| human                     | range: 19–80 years<br>mean $\pm$ s.d.:<br>53.2 $\pm$ 19.1 years |  | [ <sup>1</sup> C]PBR28 PET  | grey matter<br>frontal cortex<br>temporal cortex<br>occipital cortex<br>parietal cortex<br>hippocampus<br>thalamus        | [ <sup>11</sup> C]PBR28 PET signal (indicative of TSPO protein expression) negatively correlated with BMI  | grey matter<br>frontal cortex<br>temporal cortex<br>occipital cortex<br>parietal cortex<br>hippocampus<br>thalamus | [139]     |
| wistar rats<br>(male)     | 5 weeks at<br>beginning of the<br>experiment                    | 12 weeks of ad libitum standard<br>chow + 5% sucrose solution<br>provided in intermittent-access two-<br>bottle choice drinking paradigm<br>(24 day <sup>-1</sup> , 3 d wk <sup>-1</sup> ) | [ <sup>18</sup> F]DPA714 PET  | cerebral cortex<br>hippocampus<br>thalamus<br>caudate-putamen   | increased PET signal, indicating increased TSPO<br>protein expression  | neocortex<br>hippocampus<br>thalamus<br>caudate-putamen  | [140]     |
| C57/Bl6<br>mice<br>(male) | 15–17 weeks   | ob/ob (leptin deficient) compared<br>to wild-type<br>standard diet   | [ <sup>3</sup> H]-PK11195 PET   | coronal sections at the level of<br>hypothalamus/hippocampus<br>(stereotaxic coordinates not<br>specified)<br>whole brain | increased PET signal, indicating increased TSPO<br>protein expression  | hippocampus<br>choroid plexus<br>of third ventricle  | [141]     |
|                           | 4–7 weeks at<br>beginning of<br>the experiment                  | HFD (4 weeks) compared to standard<br>diet   | [ <sup>3</sup> H]-PK11195 saturation<br>binding on brain<br>membrane extracts | tanycytes   | increased [ <sup>3</sup> H]-PK11195 binding, indicating<br>increased TSPO protein expression   | whole brain  | [39]      |
|                           |   |  |   |   | genetic ablation of tanycytic TSPO decreased food<br>intake and weight gain compared to wild-type<br>in HFDmice; however, this ablation does not<br>impact food intake or weight gain in standard<br>diet mice<br>ICV PK11195 resulted in no change in<br>hypothalamic POMC expression of HFD mice,<br>whereas the same treatment increased<br>hypothalamic POMC expression in standard diet<br>mice |  |           |

homeostasis. We predict that TSPO modulates the ATP-dependent activation of adjacent tanycytes and appetite-regulating neurons in the ARC. TSPO knockout in both human [118] and rodent [51,119] microglia decreases ATP production. On the other hand, ATP production increases during microglial TSPO overexpression [51] or during the administration of TSPO ligands [119]. In A2/29 cells, a tanycyte cell culture model, TSPO knockout increases ATP production, indicating a potentially unique role for TSPO in tanycyte energetics [39]. The mechanism for TSPO's regulation of ATP production is unknown; however, it has been recently hypothesized that this mechanism involves TSPO-mediated phosphorylation of  $F_1F_0$ -ATP synthase [23], given that TSPO ligand administration increases the extent of this phosphorylation [120]. Therefore, TSPO may modulate the ATP-dependent tanycyte response to CSF glucosensing, ultimately modulating the activation of the appetite-regulating Agouti-related peptide (AgRP)- and proopiomelanocortin (POMC)-expressing neurons in the arcuate nucleus (figure 2b).

#### 4. TSPO interacts with RIM-BP1 to potentially influence feeding

TSPO may also influence appetite by altering synaptic plasticity. Galiègue *et al.* [121] discovered that a protein now identified as RIM-binding protein 1 (RIM-BP1) [122] binds to TSPO-specific motifs. Although RIM-BP1 is located at the pre-synaptic active zone [123], overexpression of TSPO causes an increase in RIM-BP1 protein expression in mitochondrial extracts [121]. These data suggest that TSPO interacts physically with RIM-BP1, modulating its subcellular localization. RIM-BP1, together with RIM-BP2, interact with voltage-gated calcium channels at the pre-synaptic terminal, which is an evolutionarily conserved function [123]. This interaction is believed to contribute to the positional priming of exocytic machinery [124,125], which ultimately increases the number of synaptic vesicles released [126]. Although the role of RIM-BP1 is not as critical in mammals [127] as *Drosophila* models [128,129], RIM-BP1 mutations and polymorphisms are correlated with autism in humans [130–132]. While RIM-BP1/RIM-BP2 double knockout mice show no difference to RIM-BP2 single KO mice [133], the effect of RIM-BP1 single knockout was not assessed in this study. A different RIM-BP1 single knockout study using mice showed decreased  $Ca^{2+}$  signalling in ribbon synapses [134]. Although RIM-BP1 is rarely studied in isolation, these studies show that decreased availability of RIM-BP1 at the cytomatrix active zone (CAZ) is not fully compensated for by RIM-BP2 in murine neurons, demonstrating that RIM-BP1 is essential for physiological brain function. Therefore, if TSPO interacts with RIM-BP1, it will probably precipitate a change in synaptic function.

RIM-BP1 is also implicated in appetite. Firstly, RIM-BP1 is highly expressed in brain regions associated with the limbic system [122], a key circuit in feeding-related reward [135]. RIM-BP1 antisense RNA (TSPOAP1-AS) hypermethylation at the promoter region is correlated with obesity and plasma cholesterol levels from a small human sample [136], suggesting a role for RIM-BP1 in obesity and steroid homeostasis. RIM-BP1's association with obesity, binding to TSPO and predominate expression in the limbic system suggest that RIM-BP1 may modulate TSPO's role in appetite regulation. However, no further binding studies (such as immunoprecipitation)

have been published to confirm the interaction between TSPO and RIM-BP1. Given that in the healthy brain, RIM-BP1 is predominately expressed in neurons [137], and TSPO is predominately expressed in glia [30], it is difficult to test this putative mechanism. One potential strategy to address this is to use cultured olfactory bulb cells to test the interaction of RIM-BP1 and TSPO expression in the synaptic site of the olfactory neurons and the mitral cells, given that the olfactory bulb is one of the only confirmed sites with neuronal TSPO expression in the healthy brain [21,30].

#### 5. Brain TSPO neuroplasticity in response to nutritional change

TSPO expression in the brain changes drastically in response to disease [30], potentially through a CpG methylation-mediated epigenetic mechanism [138]. It is therefore not surprising that TSPO expression is also sensitive to alterations in diet. Four studies, all conducted in the past decade, have documented alterations in TSPO as a result of diet (table 1). Interestingly, all studies assess the impact of overnutrition. These studies demonstrate an alteration in TSPO levels [139–141] and appetite-modulating function [39] due to overnutrition.

Undernutrition may also dysregulate TSPO signalling in the brain, given that anorexia nervosa is also considered to be driven by immune processes [142]. TSPO PET studies analysing patients with major depressive episodes [143] and serious self-harming behaviour [144] have included patients with anorexia nervosa. However, neither of these studies have had the statistical power necessary to analyse the effect of anorexia nervosa independently on TSPO expression. It is therefore still unknown if TSPO plays a role in conditions of depleted appetite, such as anorexia nervosa.

#### 6. Conclusion

Neuroinflammation is emerging as a pathogenic process underlying a variety of diseases, including obesity. Fortunately, this has resulted in a combined effort in the neuroscience community to develop tools to effectively measure and control neuroinflammation [34]. This work has gifted the neuroinflammation biomarker TSPO with an evolved repertoire of tracers and ligands, instilling it with excellent translational potential. However, how TSPO regulates appetite in diet-induced neuroinflammatory obesity is not widely discussed. We have outlined three putative biochemical mechanisms through which TSPO modulate appetite. Various studies that have characterized TSPO changes due to overnutrition were also synthesized, demonstrating that brain TSPO is responsive to the metabolic environment of the individual. This analysis also demonstrated the lack of research exploring TSPO's potential involvement in anorexia nervosa. By exploring the biochemical mechanisms outlined, the neurological consequences of an obesogenic Western diet can be better characterized. Additionally, these explorations may allow for the repurposing of TSPO ligands as anti-obesity medication.

**Data accessibility.** This article has no additional data.

**Authors' contributions.** J.W. is the lead author of the review. K.B. assisted in writing the review.

**Competing interests.** We declare we have no competing interests.

**Funding.** We received no funding for this study.

- Cazettes F, Cohen JJ, Yau PL, Talbot H, Convit A. 2011 Obesity-mediated inflammation may damage the brain circuit that regulates food intake. *Brain Res.* **1373**, 101–109. (doi:10.1016/j.brainres.2010.12.008)
- Samara A *et al.* 2020 Neuroinflammation and white matter alterations in obesity assessed by diffusion basis spectrum imaging. *Front. Hum. Neurosci.* **13**, 464. (doi:10.3389/fnhum.2019.00464)
- Milanski M *et al.* 2009 Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity. *J. Neurosci.* **29**, 359–370. (doi:10.1523/JNEUROSCI.2760-08.2009)
- Zhang ZG, Zhang H, Karin M, Bai H, Cai D. 2008 Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. *Cell* **135**, 61–73. (doi:10.1016/j.cell.2008.07.043)
- Choi J-Y, Park M-N, Kim C-S, Lee Y-K, Choi EY, Chun WY, Shin D-M 2017 Long-term consumption of sugar-sweetened beverage during the growth period promotes social aggression in adult mice with proinflammatory responses in the brain. *Sci. Rep.* **7**, 45693. (doi:10.1038/srep45693)
- Lopes A, Vilela TC, Taschetto L, Vuolo F, Petronilho F, Dal-Pizzol F. 2014 Evaluation of the effects of fructose on oxidative stress and inflammatory parameters in rat brain. *Mol. Neurobiol.* **50**, 1124–1130. (doi:10.1007/s12035-014-8676-y)
- Gao BM *et al.* 2017 Dietary sugars, not lipids, drive hypothalamic inflammation. *Mol. Metab.* **6**, 897–908. (doi:10.1016/j.molmet.2017.06.008)
- Yi C-X *et al.* 2012 High calorie diet triggers hypothalamic angiopathy. *Mol. Metab.* **1**, 95–100. (doi:10.1016/j.molmet.2012.08.004)
- André C *et al.* 2017 Inhibiting microglia expansion prevents diet-induced hypothalamic and peripheral inflammation. *Diabetes* **66**, 908–919. (doi:10.2337/db16-0586)
- Baufeld C, Osterloh A, Prokop S, Miller KR, Heppner FL. 2016 High-fat diet-induced brain region-specific phenotypic spectrum of CNS resident microglia. *Acta Neuropathol.* **132**, 361–375. (doi:10.1007/s00401-016-1595-4)
- Gao Y *et al.* 2014 Hormones and diet, but not body weight, control hypothalamic microglial activity. *Glia* **62**, 17–25. (doi:10.1002/glia.22580)
- Lee CH *et al.* 2018 Hypothalamic macrophage inducible nitric oxide synthase mediates obesity-associated hypothalamic inflammation. *Cell Rep.* **25**, 934–946. (doi:10.1016/j.celrep.2018.09.070)
- Valdearcos M *et al.* 2017 Microglial inflammatory signaling orchestrates the hypothalamic immune response to dietary excess and mediates obesity susceptibility. *Cell Metab.* **26**, 185–197. (doi:10.1016/j.cmet.2017.05.015)
- Douglass JD, Dorfman MD, Fasnacht R, Shaffer LD, Thaler JP. 2017 Astrocyte IKKβ/NF-κB signaling is required for diet-induced obesity and hypothalamic inflammation. *Mol. Metab.* **6**, 366–373. (doi:10.1016/j.molmet.2017.01.010)
- Zhang Y, Reichel JM, Han C, Zuniga-Hertz JP, Cai D. 2017 Astrocytic process plasticity and IKKβ/NF-κB in central control of blood glucose, blood pressure, and body weight. *Cell Metab.* **25**, 1091–1102. (doi:10.1016/j.cmet.2017.04.002)
- Bae K-R, Shim H-J, Balu D, Kim SR, Yu S-W. 2014 Translocator protein 18 kDa negatively regulates inflammation in microglia. *J. Neuroimmune Pharmacol.* **9**, 424–437. (doi:10.1007/s11481-014-9540-6)
- Lee J, Kim LE, Shim H-J, Kim E-K, Hwang WC, Min DS, Yu S-W. 2016 A translocator protein 18 kDa ligand, Ro5-4864, inhibits ATP-induced NLRP3 inflammasome activation. *Biochem. Biophys. Res. Commun.* **474**, 587–593. (doi:10.1016/j.bbrc.2016.04.080)
- Ma L, Zhang H, Liu N, Wang P-q, Guo W-z, Fu Q, Jiao L-b, Ma Y-q, Mi W-D. 2016 TSPO ligand PK11195 alleviates neuroinflammation and beta-amyloid generation induced by systemic LPS administration. *Brain Res Bull.* **121**, 192–200. (doi:10.1016/j.brainresbull.2016.02.001)
- Pozzo ED *et al.* 2019 Microglial pro-inflammatory and anti-inflammatory phenotypes are modulated by translocator protein activation. *Int. J. Mol. Sci.* **20**, 4467. (doi:10.3390/ijms20184467)
- Ibrahim KS, Craft JA, Biswas L, Spencer J, Shu X. 2020 Etifoxine reverses weight gain and alters the colonic bacterial community in a mouse model of obesity. *Biochem. Pharmacol.* **180**, 114151. (doi:10.1016/j.bcp.2020.114151)
- Anholt RR, Pedersen PL, De Souza EB, Snyder SH. 1986 The peripheral-type benzodiazepine receptor. Localization to the mitochondrial outer membrane. *J. Biol. Chem.* **261**, 576–583. (doi:10.1016/S0021-9258(17)36131-8)
- Papadopoulos BM *et al.* 2006 Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. *Trends Pharmacol. Sci.* **27**, 402–409. (doi:10.1016/j.tips.2006.06.005)
- Betlazar C, Middleton RJ, Banati R, Liu G-J. 2020 The translocator protein (TSPO) in mitochondrial bioenergetics and immune processes. *Cells* **9**, 512. (doi:10.3390/cells9020512)
- Taketani S, Kohno H, Okuda M, Furukawa T, Tokunaga R. 1994 Induction of peripheral-type benzodiazepine receptors during differentiation of mouse erythroleukemia cells. A possible involvement of these receptors in heme biosynthesis. *J. Biol. Chem.* **269**, 7527–7531. (doi:10.1016/S0021-9258(17)37318-0)
- Zeno S, Veenman L, Katz Y, Bode J, Gavish M, Zaaroor M. 2012 The 18 kDa mitochondrial translocator protein (TSPO) prevents accumulation of protoporphyrin IX. Involvement of reactive oxygen species (ROS). *Curr. Mol. Med.* **12**, 494–501. (doi:10.2174/156652412800163424)
- Shoshan-Barmatz V, Pittala S, Mizrahi D. 2019 VDACC1 and the TSPO: expression, interactions, and associated functions in health and disease states. *Int. J. Mol. Sci.* **20**, 3348. (doi:10.3390/ijms20133348)
- Betlazar C, Harrison-Brown M, Middleton RJ, Banati R, Liu G-J. 2018 Cellular sources and regional variations in the expression of the neuroinflammatory marker translocator protein (TSPO) in the normal brain. *Int. J. Mol. Sci.* **19**, 2707. (doi:10.3390/ijms19092707)
- Gong J, Szego ÉM, Leonov A, Benito E, Becker S, Fischer A, Zweckstetter M, Outeiro T, Schneider A. 2019 Translocator protein ligand protects against neurodegeneration in the MPTP mouse model of parkinsonism. *J. Neurosci.* **39**, 3752–3769. (doi:10.1523/JNEUROSCI.2070-18.2019)
- Gui Y, Marks JD, Das S, Hyman BT, Serrano-Pozo A. 2020 Characterization of the 18 kDa translocator protein (TSPO) expression in post-mortem normal and Alzheimer's disease brains. *Brain Pathol.* **30**, 151–164. (doi:10.1111/bpa.12763)
- Nutma E, Ceyzériat K, Amor S, Tsartsalis S, Millet P, Owen DR, Papadopoulos V, Tournier BB. 2021 Cellular sources of TSPO expression in healthy and diseased brain. *Int. J. Mol. Sci.* **19**, 2707. (doi:10.3390/ijms19092707)
- Brown AK *et al.* 2007 Radiation dosimetry and biodistribution in monkey and man of 11C-PBR28: a PET radioligand to image inflammation. *J. Nucl. Med.* **48**, 2072–2079. (doi:10.2967/jnumed.107.044842)
- Ji B *et al.* 2008 Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. *J. Neurosci.* **28**, 12255–12267. (doi:10.1523/JNEUROSCI.2312-08.2008)
- Pedersen MD, Minuzzi L, Wirenfeldt M, Meldgaard M, Slidsborg C, Cumming P, Finsen B. 2006 Up-regulation of PK11195 binding in areas of axonal degeneration coincides with early microglial activation in mouse brain. *Eur. J. Neurosci.* **24**, 991–1000. (doi:10.1111/j.1460-9568.2006.04975.x)
- Cumming P, Burgher B, Patkar O, Breakspear M, Vasdev N, Thomas P, Liu G-J, Banati R. 2018 Sifting through the surfeit of neuroinflammation tracers. *J. Cereb. Blood Flow Metab.* **38**, 204–224. (doi:10.1117/0271678X17748786)
- Le Fur G, Vaucher N, Perrier ML, Flamier A, Benavides J, Renault C, Dubroeuq MC, Guérémy C, Uzan A. 1983 Differentiation between two ligands for peripheral benzodiazepine binding sites, [<sup>3</sup>H]RO5-4864 and [<sup>3</sup>H]PK 11195, by thermodynamic studies. *Life Sci.* **33**, 449–457. (doi:10.1016/0024-3205(83)90794-4)
- Qiu Z-K, He J-L, Liu X, Zhang G-H, Zeng J, Nie H, Shen Y-G, Chen J-S. 2016 The antidepressant-like activity of AC-5216, a ligand for 18kDa translocator protein (TSPO), in an animal model of diabetes

- mellitus. *Sci. Rep.* **6**, 37345. (doi:10.1038/srep37345)
37. Reeder S. 1964 Amino substituted benzophenone oximes and derivatives thereof. US462930A. See <https://patents.google.com/patent/US3136815>.
  38. Nuss P, Ferreri F, Bourin M. 2019 An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action. *Neuropsychiatr. Dis. Treat* **15**, 1781–1795. (doi:10.2147/NDT.S200568)
  39. Kim S *et al.* 2020 Tanyocytic TSPO inhibition induces lipophagy to regulate lipid metabolism and improve energy balance. *Autophagy* **16**, 1200–1220. (doi:10.1080/15548627.2019.1659616)
  40. Reddy DS, Kulkarni SK. 1998 The role of GABA-A and mitochondrial diazepam-binding inhibitor receptors on the effects of neurosteroids on food intake in mice. *Psychopharmacology* **137**, 391–400. (doi:10.1007/s002130050635)
  41. Jamin N *et al.* 2005 Characterization of the cholesterol recognition amino acid consensus sequence of the peripheral-type benzodiazepine receptor. *Mol. Endocrinol.* **19**, 588–594. (doi:10.1210/me.2004-0308)
  42. Black SM, Harikrishna JA, Szklarz GD, Miller WL. 1994 The mitochondrial environment is required for activity of the cholesterol side-chain cleavage enzyme, cytochrome P450<sub>sc</sub>. *Proc. Natl Acad. Sci. USA* **91**, 7247–7251. (doi:10.1073/pnas.91.15.7247)
  43. Harikrishna JA, Black SM, Szklarz GD, Miller WL. 1993 Construction and function of fusion enzymes of the human cytochrome P450<sub>sc</sub> system. *DNA Cell Biol.* **12**, 371–379. (doi:10.1089/dna.1993.12.371)
  44. Corpéchet C *et al.* 1993 Neurosteroids: 3 alpha-hydroxy-5 alpha-pregnan-20-one and its precursors in the brain, plasma, and steroidogenic glands of male and female rats. *Endocrinology* **133**, 1003–1009. (doi:10.1210/endo.133.3.8365352)
  45. Purdy RH, Morrow AL, Moore PH, Paul SM. 1991 Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain. *Proc. Natl Acad. Sci. USA* **88**, 4553–4557. (doi:10.1073/pnas.88.10.4553)
  46. Tonon M-C *et al.* 2020 Endozepines and their receptors: structure, functions and pathophysiological significance. *Pharmacol. Ther.* **208**, 107386. (doi:10.1016/j.pharmthera.2019.06.008)
  47. Korneyev A, Pan BS, Polo A, Romeo E, Guidotti A, Costa E. 1993 Stimulation of brain pregnenolone synthesis by mitochondrial diazepam binding inhibitor receptor ligands in vivo. *J. Neurochem.* **61**, 1515–1524. (doi:10.1111/j.1471-4159.1993.tb13647.x)
  48. McCauley LD, Park CH, Lan NC, Tomich JM, Shively JE, Gee KW. 1995 Benzodiazepines and peptides stimulate pregnenolone synthesis in brain mitochondria. *Eur. J. Pharmacol.* **276**, 145–153. (doi:10.1016/0014-2999(95)00036-K)
  49. Papadopoulos V, Berkovich A, Krueger KE, Costa E, Guidotti A. 1991 Diazepam binding inhibitor and its processing products stimulate mitochondrial steroid biosynthesis via an interaction with mitochondrial benzodiazepine receptors. *Endocrinology* **129**, 1481–1488. (doi:10.1210/endo-129-3-1481)
  50. Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M. 2010 Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. *Nat. Rev. Drug Discov.* **9**, 971–988. (doi:10.1038/nrd3295)
  51. Banati RB *et al.* 2014 Positron emission tomography and functional characterization of a complete PBR/TSPO knockout. *Nat. Commun.* **5**, 5452. (doi:10.1038/ncomms6452)
  52. Morohaku K, Phuong NS, Selvaraj V. 2013 Developmental expression of translocator protein/peripheral benzodiazepine receptor in reproductive tissues. *PLoS ONE* **8**, e74509. (doi:10.1371/journal.pone.0074509)
  53. Morohaku K, Pelton SH, Daugherty DJ, Butler WR, Deng W, Selvaraj V. 2014 Translocator protein/peripheral benzodiazepine receptor is not required for steroid hormone biosynthesis. *Endocrinology* **155**, 89–97. (doi:10.1210/en.2013-1556)
  54. Selvaraj V, Tu LN, Stocco DM. 2016 Crucial role reported for TSPO in viability and steroidogenesis is a misconception. Commentary: conditional steroidogenic cell-targeted deletion of TSPO unveils a crucial role in viability and hormone-dependent steroid formation. *Front. Endocrinol. (Lausanne)* **7**, 91. (doi:10.3389/fendo.2016.00091)
  55. Lacapère JJ, Papadopoulos V. 2003 Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis. *Steroids* **68**, 569–585. (doi:10.1016/S0039-128X(03)00101-6)
  56. Fan J, Zirkin B, Papadopoulos V. 2018 Response to letter to the editor: 'Dubious conclusions on TSPO function'. *Endocrinology* **159**, 2530–2531. (doi:10.1210/en.2018-00292)
  57. Selvaraj V, Stocco DM. 2018 Letter to the editor: Dubious conclusions on TSPO function. *Endocrinology* **159**, 2528–2529. (doi:10.1210/en.2018-00052)
  58. Braestrup C, Squires RF. 1977 Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding. *Proc. Natl Acad. Sci. USA* **74**, 3805–3809. (doi:10.1073/pnas.74.9.3805)
  59. Zwain IH, Yen SS. 1999 Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. *Endocrinology* **140**, 3843–3852. (doi:10.1210/endo.140.8.6907)
  60. Mellon SH, Vaudry H. 2001 Biosynthesis of neurosteroids and regulation of their synthesis. *Int. Rev. Neurobiol.* **46**, 33–78. (doi:10.1016/S0074-7742(01)46058-2)
  61. Selvaraj V, Tu LN. 2016 Current status and future perspectives: TSPO in steroid neuroendocrinology. *J. Endocrinol.* **231**, R1–R30. (doi:10.1530/JOE-16-0241)
  62. Serra M *et al.* 1999 2-phenyl-imidazo[1,2-a]pyridine derivatives as ligands for peripheral benzodiazepine receptors: stimulation of neurosteroid synthesis and anticonflict action in rats. *Br. J. Pharmacol.* **127**, 177–187. (doi:10.1038/sj.bjp.0702530)
  63. Ravikummar B, Crawford D, Dellovade T, Savinainen A, Graham D, Liere P, Oudinet J-P, Webb M, Hering H. 2016 Differential efficacy of the TSPO ligands etifoxine and XBD-173 in two rodent models of multiple sclerosis. *Neuropharmacology* **108**, 229–237. (doi:10.1016/j.neuropharm.2016.03.053)
  64. Verleye M, Akwa Y, Liere P, Ladurelle N, Pianos A, Eychehen B, Schumacher M, Gillardin J-M. 2005 The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. *Pharmacol. Biochem. Behav.* **82**, 712–720. (doi:10.1016/j.pbb.2005.11.013)
  65. Bitran D, Foley M, Audette D, Leslie N, Frye CA. 2000 Activation of peripheral mitochondrial benzodiazepine receptors in the hippocampus stimulates allopregnanolone synthesis and produces anxiolytic-like effects in the rat. *Psychopharmacology* **151**, 64–71. (doi:10.1007/s002130000471)
  66. Petralia SM, Frye CA. 2005 In the ventral tegmental area picrotoxin blocks FGIN 1-27-induced increases in sexual behavior of rats and hamsters. *Psychopharmacology* **178**, 174–182. (doi:10.1007/s00213-004-2001-9)
  67. Zhang L-M, Qiu Z-K, Zhao N, Chen H-X, Liu Y-Q, Xu J-P, Zhang Y-Z, Yang R-F, Li Y-F. 2014 Anxiolytic-like effects of YL-IPA08, a potent ligand for the translocator protein (18 kDa) in animal models of post-traumatic stress disorder. *Int. J. Neuropsychopharmacol.* **17**, 1659–1669. (doi:10.1017/S1461145714000479)
  68. Rupprecht R, Reul JM, Trapp T, van Steensel B, Wetzel C, Damm K, Ziegängsberger W, Holsboer F. 1993 Progesterone receptor-mediated effects of neuroactive steroids. *Neuron* **11**, 523–530. (doi:10.1016/0896-6273(93)90156-L)
  69. Rupprecht R, Hauser CAE, Trapp T, Holsboer F. 1996 Neurosteroids: molecular mechanisms of action and psychopharmacological significance. *J. Steroid Biochem. Mol. Biol.* **56**, 163–168. (doi:10.1016/0960-0760(95)00233-2)
  70. Gee KW, McCauley LD, Lan NC. 1995 A putative receptor for neurosteroids on the GABAA receptor complex: the pharmacological properties and therapeutic potential of epalons. *Crit. Rev. Neurobiol.* **9**, 207–227.
  71. Lambert JJ, Belelli D, Peden DR, Vardy AW, Peters JA. 2003 Neurosteroid modulation of GABAA receptors. *Prog. Neurobiol.* **71**, 67–80. (doi:10.1016/j.pneurobio.2003.09.001)
  72. Majewska MD. 1992 Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. *Prog. Neurobiol.* **38**, 379–395. (doi:10.1016/0301-0082(92)90025-A)
  73. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. 1986 Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor.

- Science* **232**, 1004–1007. (doi:10.1126/science.2422758)
74. Bellelli D, Hogenkamp D, Gee KW, Lambert JJ. 2020 Realising the therapeutic potential of neuroactive steroid modulators of the GABAA receptor. *Neurobiol. Stress* **12**, 100207. (doi:10.1016/j.jynstr.2019.100207)
  75. Suyama S, Yada T. 2018 New insight into GABAergic neurons in the hypothalamic feeding regulation. *J. Physiol. Sci.* **68**, 717–722. (doi:10.1007/s12576-018-0622-8)
  76. Holmberg E *et al.* 2018 Allopregnanolone involvement in feeding regulation, overeating and obesity. *Front. Neuroendocrinol.* **48**, 70–77. (doi:10.1016/j.yfrne.2017.07.002)
  77. Wingstrand KG. 1951 *The structure and development of the avian pituitary from a comparative and functional viewpoint*. Lund, Sweden: CWK.
  78. Horstmann E. 1954 [The fiber glia of selacean brain]. *Z. Zellforsch Mikrosk. Anat.* **39**, 588–617. (doi:10.1007/BF00334758)
  79. Vigh B *et al.* 2004 The system of cerebrospinal fluid-contacting neurons: its supposed role in the nonsynaptic signal transmission of the brain. *Histol. Histopathol.* **19**, 607–628.
  80. Goodman T, Hajihosseini MK. 2021 Hypothalamic tanycytes—masters and servants of metabolic, neuroendocrine, and neurogenic functions. *Front. Neurosci.* **9**, 387. (doi:10.3389/fnins.2015.00387)
  81. Campbell JN *et al.* 2017 A molecular census of arcuate hypothalamus and median eminence cell types. *Nat. Neurosci.* **20**, 484–496. (doi:10.1038/nn.4495)
  82. Chen R, Wu X, Jiang L, Zhang Y. 2017 Single-cell RNA-Seq reveals hypothalamic cell diversity. *Cell Rep.* **18**, 3227–3241. (doi:10.1016/j.celrep.2017.03.004)
  83. Pasquettaz R, Kolotuev I, Rohrbach A, Gouelle C, Pellerin L, Langlet F. 2021 Peculiar protrusions along tanycyte processes face diverse neural and nonneural cell types in the hypothalamic parenchyma. *J. Comp. Neurol.* **529**, 553–575. (doi:10.1002/cne.24965)
  84. Rodríguez E, Guerra M, Peruzzo B, Blázquez JL. 2019 Tanycytes: a rich morphological history to underpin future molecular and physiological investigations. *J. Neuroendocrinol.* **31**, e12690. (doi:10.1111/jne.12690)
  85. Bolborea M, Langlet F. 2021 What is the physiological role of hypothalamic tanycytes in metabolism? *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **320**, R994–R1003. (doi:10.1152/ajpregu.00296.2020)
  86. Varga B, Markó K, Hádinger N, Jelítai M, Demeter K, Tihanyi K, Vas Á, Madarász E. 2009 Translocator protein (TSPO 18 kDa) is expressed by neural stem and neuronal precursor cells. *Neurosci. Lett.* **462**, 257–262. (doi:10.1016/j.neulet.2009.06.051)
  87. Hegen H, Walde J, Auer M, Deisenhammer F. 2018 Cerebrospinal fluid: serum glucose ratio in the ventricular and lumbar compartments: implications for clinical practice. *Eur. J. Neurol.* **25**, 373–379. (doi:10.1111/ene.13513)
  88. Brawer JR. 1972 The fine structure of the ependymal tanycytes at the level of the arcuate nucleus. *J. Comp. Neurol.* **145**, 25–41. (doi:10.1002/cne.901450103)
  89. Bestetti G, Rossi GL. 1980 Hypothalamic lesions in rats with long-term streptozotocin-induced diabetes mellitus. *Acta Neuropathol.* **52**, 119–127. (doi:10.1007/BF00688009)
  90. Frayling C, Britton R, Dale N. 2011 ATP-mediated glucosensing by hypothalamic tanycytes. *J. Physiol.* **589**, 2275–2286. (doi:10.1113/jphysiol.2010.202051)
  91. Palma-Chavez A *et al.* 2019 Glucose increase DAGL $\alpha$  levels in tanycytes and its inhibition alters orexigenic and anorexigenic neuropeptides expression in response to glucose. *Front. Endocrinol.* **10**, 647. (doi:10.3389/fendo.2019.00647)
  92. Benford H, Bolborea M, Pollatzek E, Lossow K, Hermans-Borgmeyer I, Liu B, Meyerhof W, Kasparov S, Dale N. 2017 A sweet taste receptor-dependent mechanism of glucosensing in hypothalamic tanycytes. *Glia* **65**, 773–789. (doi:10.1002/glia.23125)
  93. Lazutkaite G, Soldà A, Lossow K, Meyerhof W, Dale N. 2017 Amino acid sensing in hypothalamic tanycytes via umami taste receptors. *Mol. Metab.* **6**, 1480–1492. (doi:10.1016/j.molmet.2017.08.015)
  94. Geller S, Arribat Y, Netzahualcoyotzi C, Lagarrigue S, Carneiro L, Zhang L, Amati F, Lopez-Mejia IC, Pellerin L. 2019 Tanycytes regulate lipid homeostasis by sensing free fatty acids and signaling to key hypothalamic neuronal populations via FGF21 secretion. *Cell Metab.* **30**, 833–844.e7. (doi:10.1016/j.cmet.2019.08.004)
  95. Hofmann K, Lamberz C, Piotrowitz K, Offermann N, But D, Scheller A, Al-Amoudi A, Kuerschner L. 2017 Tanycytes and a differential fatty acid metabolism in the hypothalamus. *Glia* **65**, 231–249. (doi:10.1002/glia.23088)
  96. Langlet F. 2019 Tanycyte gene expression dynamics in the regulation of energy homeostasis. *Front. Endocrinol.* **10**, 286. (doi:10.3389/fendo.2019.00286)
  97. Mullier A, Bouret SG, Prevot V, Dehouck B. 2010 Differential distribution of tight junction proteins suggests a role for tanycytes in blood-hypothalamus barrier regulation in the adult mouse brain. *J. Comp. Neurol.* **518**, 943–962. (doi:10.1002/cne.22273)
  98. Langlet F *et al.* 2013 Tanycytic VEGF-A boosts blood-hypothalamus barrier plasticity and access of metabolic signals to the arcuate nucleus in response to fasting. *Cell Metab.* **17**, 607–617. (doi:10.1016/j.cmet.2013.03.004)
  99. Balland E *et al.* 2014 Hypothalamic tanycytes are an ERK-gated conduit for leptin into the brain. *Cell Metab.* **19**, 293–301. (doi:10.1016/j.cmet.2013.12.015)
  100. Collden G, Balland E, Parkash J, Caron E, Langlet F, Prevot V, Bouret SG. 2015 Neonatal overnutrition causes early alterations in the central response to peripheral ghrelin. *Mol. Metab.* **4**, 15–24. (doi:10.1016/j.molmet.2014.10.003)
  101. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S. 2001 A role for ghrelin in the central regulation of feeding. *Nature* **409**, 194–198. (doi:10.1038/35051587)
  102. Pinto S, Roseberry AG, Liu H, Diano S, Shanabrough M, Cai X, Friedm JM. 2004 Rapid rewiring of arcuate nucleus feeding circuits by leptin. *Science* **304**, 110–115. (doi:10.1126/science.1089459)
  103. Barahona MJ *et al.* 2018 Glial hypothalamic inhibition of GLUT2 expression alters satiety, impacting eating behavior. *Glia* **66**, 592–605. (doi:10.1002/glia.23267)
  104. Elizondo-Vega R, Cortés-Campos C, Barahona MJ, Carril C, Ordenes P, Salgado M, Oyarce K, de los Angeles García-Robles M. 2016 Inhibition of hypothalamic MCT1 expression increases food intake and alters orexigenic and anorexigenic neuropeptide expression. *Sci. Rep.* **6**, 33606. (doi:10.1038/srep33606)
  105. Sanders NM, Dunn-Meynell AA, Levin BE. 2004 Third ventricular alloxan reversibly impairs glucose counterregulatory responses. *Diabetes* **53**, 1230–1236. (doi:10.2337/diabetes.53.5.1230)
  106. Uranga RM *et al.* 2017 Adenovirus-mediated suppression of hypothalamic glucokinase affects feeding behavior. *Sci. Rep.* **7**, 3697. (doi:10.1038/s41598-017-03928-x)
  107. Lee DA *et al.* 2012 Tanycytes of the hypothalamic median eminence form a diet-responsive neurogenic niche. *Nat. Neurosci.* **15**, 700–702. (doi:10.1038/nn.3079)
  108. Yoo S *et al.* 2020 Tanycyte ablation in the arcuate nucleus and median eminence increases obesity susceptibility by increasing body fat content in male mice. *Glia* **68**, 1987–2000. (doi:10.1002/glia.23817)
  109. Helfer G, Ross AW, Thomson LM, Mayer CD, Stoney PN, McCaffery PJ, Morgan PJ. 2016 A neuroendocrine role for chemerin in hypothalamic remodelling and photoperiodic control of energy balance. *Sci. Rep.* **6**, 26830. (doi:10.1038/srep26830)
  110. Guillebaud F *et al.* 2017 Glial endozepines inhibit feeding-related autonomic functions by acting at the brainstem level. *Front. Neurosci.* **11**, 308. (doi:10.3389/fnins.2017.00308)
  111. Guillebaud F *et al.* 2020 Glial endozepines reverse high-fat diet-induced obesity by enhancing hypothalamic response to peripheral leptin. *Mol. Neurobiol.* **57**, 3307–3333. (doi:10.1007/s12035-020-01944-z)
  112. Lanfray D *et al.* 2013 Gliotransmission and brain glucose sensing: critical role of endozepines. *Diabetes* **62**, 801–810. (doi:10.2337/db11-0785)
  113. Compère V, Lanfray D, Castel H, Morin F, Leprince J, Dureuil B, Vaudry H, Pelletier G, Tonon MC. 2010 Acute food deprivation reduces expression of diazepam-binding inhibitor, the precursor of the anorexigenic octadecanuropeptide ODN, in mouse glial cells. *J. Mol. Endocrinol.* **44**, 295–299. (doi:10.1677/JME-09-0176)
  114. Slobodyansky E, Antkiewicz-Michaluk L, Martin B. 1994 Purification of a novel DBI processing product, DBI39-75, and characterization of its binding site in



- rat brain. *Regul. Pept.* **50**, 29–35. (doi:10.1016/0167-0115(94)90188-0)
115. Recabal A *et al.* 2018 Connexin-43 gap junctions are responsible for the hypothalamic tanyocyte-coupled network. *Front. Cell Neurosci.* **12**, 406. (doi:10.3389/fncel.2018.00406)
  116. Bolborea M, Pollatzek E, Benford H, Sotelo-Hitschfeld T, Dale N. 2020 Hypothalamic tanyocytes generate acute hyperphagia through activation of the arcuate neuronal network. *Proc. Natl Acad. Sci. USA* **117**, 14473–14481. (doi:10.1073/pnas.1919887117)
  117. Xu J *et al.* 2016 P2X4 receptor reporter mice: sparse brain expression and feeding-related presynaptic facilitation in the arcuate nucleus. *J. Neurosci.* **36**, 8902–8920. (doi:10.1523/JNEUROSCI.1496-16.2016)
  118. Milenkovic VM *et al.* 2019 CRISPR-Cas9 mediated TSP0 gene knockout alters respiration and cellular metabolism in human primary microglia cells. *Int. J. Mol. Sci.* **20**, 3359. (doi:10.3390/ijms20133359)
  119. Bader S, Wolf L, Milenkovic VM, Gruber M, Nothdurfter C, Rupprecht R, Wetzel CH. 2019 Differential effects of TSP0 ligands on mitochondrial function in mouse microglia cells. *Psychoneuroendocrinology* **106**, 65–76. (doi:10.1016/j.psyneuen.2019.03.029)
  120. Krestinina OV, Grachev DE, Odinkova IV, Reiser G, YuV E, Azarashvili TS. 2009 Effect of peripheral benzodiazepine receptor (PBR/TSP0) ligands on opening of Ca<sup>2+</sup>-induced pore and phosphorylation of 3.5-kDa polypeptide in rat brain mitochondria. *Biochemistry Moscow* **74**, 421–429. (doi:10.1134/S0006297909040105)
  121. Galiègue S, Jbilo O, Combes T, Bribes E, Carayon P, Le Fur G, Casellas P. 1999 Cloning and characterization of PRAX-1: a new protein that specifically interacts with the peripheral benzodiazepine receptor. *J. Biol. Chem.* **274**, 2938–2952. (doi:10.1074/jbc.274.5.2938)
  122. Wang Y, Sugita S, Südhof TC. 2000 The RIM/NIM family of neuronal C2 domain proteins. Interactions with Rab3 and a new class of Src homology 3 domain proteins. *J. Biol. Chem.* **275**, 20033–20044. (doi:10.1074/jbc.M909008199)
  123. Kushibiki Y, Suzuki T, Jin Y, Taru H. 2019 RIMB-1/RIM-binding protein and UNC-10/RIM redundantly regulate presynaptic localization of the voltage-gated calcium channel in *Caenorhabditis elegans*. *J. Neurosci.* **39**, 8617–8631. (doi:10.1523/JNEUROSCI.0506-19.2019)
  124. Gao T, Zhang Z, Yang Y, Zhang H, Li N, Liu B. 2021 Impact of RIM-BPs in neuronal vesicles release. *Brain Res. Bull.* **170**, 129–136. (doi:10.1016/j.brainresbull.2021.02.012)
  125. Neher E, Sakaba T. 2008 Multiple roles of calcium ions in the regulation of neurotransmitter release. *Neuron* **59**, 861–872. (doi:10.1016/j.neuron.2008.08.019)
  126. Sheng J *et al.* 2012 Calcium-channel number critically influences synaptic strength and plasticity at the active zone. *Nat. Neurosci.* **15**, 998–1006. (doi:10.1038/nn.3129)
  127. Acuna C, Liu X, Südhof TC. 2016 How to make an active zone: unexpected universal functional redundancy between RIMs and RIM-BPs. *Neuron* **91**, 792–807. (doi:10.1016/j.neuron.2016.07.042)
  128. Hibino H, Pironkova R, Onwumere O, Vologodskaja M, Hudspeth AJ, Lesage F. 2002 RIM binding proteins (RBPs) couple Rab3-interacting molecules (RIMs) to voltage-gated Ca<sup>2+</sup> channels. *Neuron* **34**, 411–423. (doi:10.1016/S0896-6273(02)00667-0)
  129. Liu KSY *et al.* 2011 RIM-binding protein, a central part of the active zone, is essential for neurotransmitter release. *Science* **334**, 1565–1569. (doi:10.1126/science.1212991)
  130. Bucan M *et al.* 2009 Genome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genes. *PLoS Genet.* **5**, e1000536. (doi:10.1371/journal.pgen.1000536)
  131. Krumm N *et al.* 2015 Excess of rare, inherited truncating mutations in autism. *Nat. Genet.* **47**, 582–588. (doi:10.1038/ng.3303)
  132. Pinto D *et al.* 2010 Functional impact of global rare copy number variation in autism spectrum disorders. *Nature* **466**, 368–372. (doi:10.1038/nature09146)
  133. Grauel MK *et al.* 2016 RIM-binding protein 2 regulates release probability by fine-tuning calcium channel localization at murine hippocampal synapses. *Proc. Natl Acad. Sci. USA* **113**, 11615–11620. (doi:10.1073/pnas.1605256113)
  134. Luo F, Liu X, Südhof TC, Acuna C. 2017 Efficient stimulus-secretion coupling at ribbon synapses requires RIM-binding protein tethering of L-type Ca<sup>2+</sup> channels. *Proc. Natl Acad. Sci. USA* **114**, E8081–E8090. (doi:10.1073/pnas.1702991114)
  135. Jacques A, Chaaya N, Beecher K, Ali SA, Belmer A, Bartlett S. 2019 The impact of sugar consumption on stress driven, emotional and addictive behaviors. *Neurosci. Biobehav. Rev.* **103**, 178–199. (doi:10.1016/j.neubiorev.2019.05.021)
  136. Yim N-H, Cha MH, Kim MS. 2020 Hypermethylation of the TSP0AP1-AS1 promoter may be associated with obesity in overweight/obese Korean subjects. *Int. J. Mol. Sci.* **21**, 3307.
  137. Chardenot P, Roubert C, Galiègue S, Casellas P, Le Fur G, Soubrié P, Oury-Donat F. 2002 Expression profile and up-regulation of PRAX-1 mRNA by antidepressant treatment in the rat brain. *Mol. Pharmacol.* **62**, 1314–1320. (doi:10.1124/mol.62.6.1314)
  138. Middleton RJ, Kam WW-Y, Liu G-J, Banati RB. 2017 Epigenetic silencing of the human 18 kDa translocator protein in a T cell leukemia cell line. *DNA Cell Biol.* **36**, 103–108. (doi:10.1089/dna.2016.3385)
  139. Tuisku J *et al.* 2019 Effects of age, BMI and sex on the glial cell marker TSP0—a multicentre [11C]PBR28 HRRT PET study. *Eur. J. Nucl. Med. Mol. Imaging* **46**, 2329–2338. (doi:10.1007/s00259-019-04403-7)
  140. Patkar OL *et al.* 2021 A binge high sucrose diet provokes systemic and cerebral inflammation in rats without inducing obesity. *Sci. Rep.* **11**, 11252. (doi:10.1038/s41598-021-90817-z)
  141. Giannaccini G, *et al.* 2011 Serotonin transporter (SERT) and translocator protein (TSP0) expression in the obese ob/ob mouse. *BMC Neurosci.* **12**, 18. (doi:10.1186/1471-2202-12-18)
  142. Dalton B, Campbell IC, Chung R, Breen G, Schmidt U, Himmerich H. 2018 Inflammatory markers in anorexia nervosa: an exploratory study. *Nutrients* **10**, 1573. (doi:10.3390/nu10111573)
  143. Setiawan E *et al.* 2015 Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. *JAMA Psychiatry* **72**, 268–275. (doi:10.1001/jamapsychiatry.2014.2427)
  144. Baharikhoo P. 2021 Investigating translocator protein binding in borderline personality disorder with serious self-harm behavior: an [18 F] FEPPA positron emission tomography study. Thesis. See <https://tspace.library.utoronto.ca/handle/1807/104923>.